Hepa-Merz

Hepa-Merz is a pharmaceutical product marketed in the European Union that contains the active ingredient ornithine aspartate. It is supplied as an oral formulation, though specific dosage form and strength are not disclosed in the label. Ornithine aspartate is a naturally occurring amino‑acid derivative that is used to support liver metabolism and ammonia detoxification. The product is intended for adult patients generally under medical supervision.

Hepa-Merz is indicated for clinical situations where support of hepatic function and reduction of elevated blood ammonia are desired, particularly in patients with chronic liver disease.

- Adjunct therapy for patients with cirrhosis to help maintain normal ammonia levels. - Supportive care in hepatic encephalopathy to improve neurocognitive symptoms. - Nutritional supplementation in liver transplant candidates to aid metabolic recovery. - Management of mild hyperammonemia in non‑alcoholic fatty liver disease. - Use in clinical trials evaluating liver‑protective agents.

Ornithine aspartate is generally well tolerated, but patients may experience a range of adverse reactions that vary in frequency and severity.

Common: - Mild gastrointestinal discomfort such as nausea or abdominal bloating. - Transient headache or dizziness, especially after the first dose. - Slight increase in serum urea levels without clinical significance. - Temporary skin flushing or mild erythema at the injection site (if parenteral form used).

Serious: - Allergic reactions including urticaria, angioedema, or anaphylaxis. - Significant elevation of liver enzymes indicating hepatic injury.

When prescribing Hepa-Merz, clinicians should consider several precautionary measures to ensure safe use in diverse patient populations.

- Assess baseline liver function tests before initiating therapy. - Use with caution in patients with severe renal impairment. - Monitor ammonia levels periodically during treatment. - Avoid use in known hypersensitivity to ornithine or aspartate. - Adjust dose in elderly patients due to altered metabolism. - Discontinue if signs of hepatic decompensation appear.

Ornithine aspartate may interact with other medications or substances that affect ammonia metabolism or liver function.

Avoid: - Concomitant use with high‑dose lactulose that may mask clinical response. - Combining with other ammonia‑lowering agents without medical supervision.

Use with caution: - Alcohol consumption, which can exacerbate liver injury. - Certain diuretics that may alter electrolyte balance. - Herbal supplements such as kava or valerian that affect hepatic enzymes.